Partner Fund Management Has Confidence In Blueprint Medicines Corp (BPMC)

Page 1 of 13

Chris James’ Partner Fund Management revealed a 5.1% position in Blueprint Medicines Corp (NASDAQ:BPMC) last week. At the end of 2015 Chris James’ hedge fund owned a million shares of the biotech company. Last week’s filings indicated that Partner Fund Management boosted its position by about 37% during the first quarter probably taking advantage of the decline in share prices. Blueprint Medicines Corp was quite popular among healthcare hedge funds such as BVF, Visium, RA Capital, and Perceptive Advisors. Hedge funds tracked by Insider Monkey collectively owned nearly 30% of BPMC’s outstanding shares at the end of 2015.

Here are the details of Partner Fund Management’s recent purchases:

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Partner Fund Management 0 1,359,946 0 5.0%
Partner Fund Management GP 0 1,359,946 0 5.0%
Partner Investment Management 0 18,788 0 0.1%
Partner Investment Management GP 0 18,788 0 0.1%
Brian D. Grossman 0 1,378,734 0 5.1%
Christopher M. James 0 1,378,734 0 5.1%

Follow Christopher Medlock James's Partner Fund Management

Page 1 of 13 – SEC Filing

Washington, D.C.  20549
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No.      )*
Blueprint Medicines Corporation
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
(CUSIP Number)
March 18, 2016
Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow Blueprint Medicines Corp (NASDAQ:BPMC)

Page 1 of 13